Sequoia Financial Advisors LLC Has $3.14 Million Holdings in Elevance Health, Inc. $ELV

Sequoia Financial Advisors LLC increased its position in shares of Elevance Health, Inc. (NYSE:ELV) by 19.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,952 shares of the company’s stock after purchasing an additional 1,435 shares during the period. Sequoia Financial Advisors LLC’s holdings in Elevance Health were worth $3,138,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ELV. Sound View Wealth Advisors Group LLC increased its holdings in Elevance Health by 3.0% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after buying an additional 29 shares during the period. Fulton Breakefield Broenniman LLC lifted its holdings in shares of Elevance Health by 3.6% during the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock worth $289,000 after acquiring an additional 29 shares during the period. Perigon Wealth Management LLC boosted its position in shares of Elevance Health by 2.2% during the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock valued at $481,000 after acquiring an additional 29 shares in the last quarter. Savvy Advisors Inc. boosted its position in shares of Elevance Health by 3.2% during the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after acquiring an additional 30 shares in the last quarter. Finally, Detalus Advisors LLC increased its stake in Elevance Health by 1.8% in the third quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after acquiring an additional 31 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance beat first-quarter expectations and raised EPS guidance, which is helping support investor confidence in the company’s near-term outlook. A Look At Elevance Health (ELV) Valuation After Q1 Beat And Raised EPS Guidance
• Positive Sentiment: Zacks Research lifted FY2026 EPS estimates to $26.79 from $25.53, matching the consensus estimate and signaling stronger expected earnings this year.
• Positive Sentiment: Zacks also raised FY2027 EPS estimates to $28.51 from $28.40, and increased its Q2 2027 forecast to $7.23 from $7.20, suggesting analysts still see healthy longer-term profitability.

Elevance Health Trading Up 1.3%

ELV opened at $377.66 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $312.92 and a two-hundred day moving average price of $332.13. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $424.24. The stock has a market capitalization of $82.01 billion, a PE ratio of 16.06, a PEG ratio of 2.15 and a beta of 0.66.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same period last year, the company earned $11.97 EPS. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts anticipate that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is 29.26%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ELV. Guggenheim raised their price target on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Truist Financial dropped their target price on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a report on Monday, April 13th. Robert W. Baird raised their target price on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research report on Thursday, April 23rd. Finally, Citigroup raised Elevance Health to a “buy” rating in a research note on Wednesday, April 29th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $384.58.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.